Stockpolly
Search
RAPP · NASDAQ · Biotechnology

Rapport Therapeutics (RAPP)

Develops RAP-targeted neuromedicines, with RAP-219 advancing across seizure and bipolar mania programs.

$48.69
At close+0.13 (+0.27%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000000200
Cost of revenue000000000000
Gross profit0000000000200
101517212224272930394461
Research & development81213161617202322303351
2355668788119
General & administrative2355668788119
Operating income−10−15−17−21−22−24−27−29−30−39−24−61
11−6344333544
Interest income112344333544
Other non-operating income0−1000000000−4
Income before tax−9−14−23−18−18−20−24−27−27−34−20−57
Income tax expense000000000000
Net income from continuing operations−9−14−23−18−18−20−24−27−27−34−20−57
Net income−9−14−23−18−18−20−24−27−27−34−20−57
EPS, basic−$0.05−$0.07−$0.12−$0.50−$0.50−$0.57−$0.68−$0.75−$0.71−$0.72−$0.42−$1.19
EPS, diluted−$0.05−$0.07−$0.12−$0.50−$0.50−$0.57−$0.68−$0.75−$0.71−$0.72−$0.42−$1.19
Weighted average shares, basic19——201919193538474747
Weighted average shares, diluted19——201919193538474747
EBITDA−10−13−17−21−21−23−27−29−30−38−24−56
Depreciation & amortization000000000000
EBIT−10−13−17−21−22−24−27−29−30−39−24−57